CODX

Co-Diagnostics, Inc. · Healthcare

Co-Diagnostics, Inc. (CODX) has 14 SEC Form 4 filings (20 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: May 27, 2026.

  • Industry:Biotechnology
  • CEO:Dwight Egan
  • Employees:115
  • HQ:Salt Lake City, UT, US
  • IPO:2017-07-12

No open-market insider trades for CODX (Co-Diagnostics, Inc.) in the last 365 days.

Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.

Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.

See all Form 4 filings on SEC EDGAR ↗

Earnings: last 7 quarters

EstimatedActual

Frequently asked questions

How many SEC Form 4 insider filings does CODX have?

Co-Diagnostics, Inc. (CODX) has 14 SEC Form 4 filings (20 transaction rows) in the rolling 365-day window, disclosed by 0 distinct insiders. Most recent filing: May 27, 2026.

When was the most recent SEC Form 4 filing for CODX?

The most recent Form 4 filing for CODX on Tracefour is dated May 27, 2026.

Can I get alerts for CODX insider trading?

Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Co-Diagnostics, Inc. (CODX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.

Related companies

Co-Diagnostics, Inc. is in the Healthcare sector.